Marisa Wexler, MS,  senior science writer—

A combination therapy using Blenrep (belantamab mafodotin) was more effective at extending life in people with relapsed or refractory multiple myeloma than a combo treatment…

The U.S. Food and Drug Administration (FDA) has approved the cell therapy Aucatzyl (obecabtagene autoleucel) to treat adults with relapsed or refractory precursor B-cell acute…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-108, an experimental virus-based therapy that Mustang Bio is developing for…

Johnson & Johnson (J&J) is asking regulatory authorities in the European Union to approve a combination treatment based on the subcutaneous, or under-the-skin, formulation…

A single infusion of the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) was sufficient to control disease activity in most multiple myeloma patients who…

Arcellx and Kite Pharma are planning to launch a Phase 3 clinical trial, dubbed iMMagine-3, to test their cell therapy anitocabtagene…

At its 15th annual gala, held in New York City this April, the International Myeloma Foundation (IMF) raised more than $675,000 — monies the…

A dysregulated immune response against viruses that cause hepatitis may lead to some cases of multiple myeloma (MM) — and in these cases, treating…

Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to…

The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to…